Notably, blockade of PD-1 in cancer treatment results in beneficial therapeutic outcomes dependent on IFN-γ producing T cells [28], and dependence on T-bet to secrete IFN-γ is distinct for CD4+ and CD8+ T cells [29]. The gene discussed is CD8A; the disease is cancer.